As previously reported in a Current Report on Form 8-K/A filed with the Securities and Exchange Commission on December 27, 2023, Onconetix, Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with an investor (the “Investor”) for a private placement of $5.0 million (the “Aggregate Purchase ...

Dec 12, 2024 · The consolidated financial statements of Onconetix, Inc., formerly known as Blue Water Vaccines Inc., as of and for the year ended December 31, 2022, appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, have been audited by CBIZ CPAs P.C. (formerly Mayer Hoffman McCann, P.C.), independent registered ...

On September 24, 2024, Onconetix, Inc. (the “ Company ”) effected a reverse stock split (the “ Reverse Stock Split ”) of all of the outstanding shares of the Company’s issued and outstanding common stock at a ratio of one-for-forty (1:40). Unless otherwise indicated, all share amounts and share prices disclosed herein are presented on ...

The Onconetix Board unanimously recommends that Onconetix stockholders vote “FOR” each of the foregoing proposals.

Dr. Singh, a director since February 2024, is a Partner at Silicon Valley based Artiman Ventures, focused on early-stage technology and life science investments, with over $1 billion in assets under management.

Dec 19, 2023 · The Investor Relations website contains information about Onconetix, Inc.'s business for stockholders, potential investors, and financial analysts.

Apr 20, 2023 · Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader Focus Company to Host a Conference call Today, April 20 th , at 8:30am EDT to Discuss Asset Purchase and Company Transformation

On December 15, 2023, the Company closed its acquisition of Proteomedix and introduced Onconetix, Inc. as the new name for the combined company.

Mar 31, 2024 · Onconetix, Inc. Former Name if Applicable : Address of Principal Executive Office (Street and Number) 201 E. Fifth Street, Suite 1900 . City, State and Zip Code: Cincinnati, Ohio 45202 . PART II - RULES 12b-25(b) AND (c)

This Schedule 13D is filed (this “Schedule 13D”) by the Reporting Person (as identified above and defined below) with respect to the common stock, par value $0.00001 (“Shares”) of Onconetix, Inc., a Delaware company, with its principal executive offices located at 201 E.